Curis, Inc.
61 Moulton Street
Cambridge
Massachusetts
02138
Tel: 617-876-0086
Fax: 617-876-0866
Website: http://www.curis.com/
502 articles with Curis, Inc.
-
Curis Provides Fourth Quarter 2022 Business Update
3/13/2023
Curis, Inc. today reported its business update and financial results for the fourth quarter ended December 31, 2022.
-
Curis Reschedules Fourth Quarter 2022 Business Update and Conference Call
3/8/2023
Curis, Inc. (NASDAQ: CRIS) announced today that it is rescheduling its fourth quarter business update and quarterly investor conference call previously scheduled for Thursday, March 9, 2023 at 4:30 p.m. ET to Monday, March 13, 2023 at 8:30 a.m. ET.
-
Curis to Release Fourth Quarter 2022 Financial Results and Hold Conference Call on March 9, 2023
3/2/2023
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its fourth quarter 2022 financial results on Thursday, March 9, 2023, after the close of U.S. markets.
-
Curis Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS
12/12/2022
Curis, Inc. (NASDAQ: CRIS) today announced positive updated clinical data from the ongoing open label Phase 1a dose escalation study of emavusertib (CA-4948), a novel, small molecule IRAK-4 inhibitor, as a monotherapy in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) or high risk myelodysplastic syndromes (hrMDS) in both targeted and non-targeted populations.
-
Curis to Host Webcast to Discuss Updated Emavusertib Clinical Data in Leukemia
12/6/2022
Curis, Inc. announced that it will host a webcast on Monday, December 12, 2022, at 10:00 a.m. ET to discuss new data from the TakeAim Leukemia trial of emavusertib, including data presented at the 64th American Society of Hematology Annual Meeting.
-
Curis Provides Third Quarter 2022 Business Update
11/9/2022
Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, reported its business update and financial results for the third quarter ended September 30, 2022.
-
Curis Announces Three Presentations at SITC 2022
11/7/2022
Curis, Inc. announced that the Company along with its collaborative partners will be presenting three posters at the upcoming 37th Annual Meeting of the Society for Immunotherapy of Cancer being held in Boston, MA and virtually from November 8th to November 12th.
-
Curis to Release Third Quarter 2022 Financial Results and Hold Conference Call on November 9, 2022
11/2/2022
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its third quarter 2022 financial results on Wednesday, November 9, 2022, after the close of U.S. markets.
-
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - October 07, 2022
10/7/2022
Curis, Inc. announced that on October 3, 2022, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 121,650 shares of Curis common stock to two new employees, with a grant date of October 3, 2022.
-
Curis Announces Date for the 1st Symposium on IRAK4 in Cancer
10/3/2022
Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced the 1st Symposium on IRAK4 in Cancer taking place virtually on October 7, 9:00am-1:00pm ET.
-
Curis Announces Date for the 2nd Annual VISTA Symposium
9/20/2022
Curis, Inc. announced that the 2nd Annual VISTA Symposium will take place virtually on September 23, 9:00am-1:00pm ET.
-
Curis to Present at Upcoming Healthcare Conferences in September 2022
9/7/2022
Curis, Inc. announced that James Dentzer, President and Chief Executive Officer of Curis, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14, 2022 at 4:00 p.m. ET in New York, NY.
-
FDA Allows Patient Enrollment to Resume in Monotherapy Dose Escalation of Emavusertib in TakeAim Leukemia Study
8/30/2022
Curis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has notified Curis that it may resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study.
-
Curis announced that the FDA has allowed patient enrollment to resume in the monotherapy phase of its TakeAim Leukemia Phase I/II trial studying emavusertib.
-
The FDA is busy accepting drug applications, granting specialty designations and approving drugs for market. Here's a look at this week's FDA activity.
-
FDA Lifts Partial Clinical Hold on the TakeAim Lymphoma Study of Emavusertib
8/18/2022
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the TakeAim Lymphoma Phase 1/2 study of emavusertib after reviewing the comprehensive data package submitted by Curis.
-
Curis Reports Second Quarter 2022 Financial Results and Business Update
8/4/2022
Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, reported its financial results for the second quarter ended June 30, 2022 and provided business updates.
-
Curis Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - July 29, 2022
7/29/2022
Curis, Inc. announced that on July 22, 2022, the independent Compensation Committee of the Board of Directors of Curis approved the grant of an inducement stock option to purchase a total of 540,000 shares of Curis common stock to a new employee, with a grant date of July 26, 2022, which is the employee's date of hire.
-
Curis to Release Second Quarter 2022 Financial Results and Hold Conference Call on August 4, 2022
7/28/2022
Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced that the Company will release its second quarter 2022 financial results on Thursday, August 4, 2022, after the close of U.S. markets.
-
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - July 07, 2022
7/7/2022
Curis, Inc. announced that on July 5, 2022, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 873,750 shares of Curis common stock to sixteen new employees, with a grant date of July 5, 2022.